COVID-19
Conditions
Interventions
Control group:N/A
Medication group:N/A
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Exposure group: 1,Patients with SARS-CoV-2 infection admitted to hospital from 1 January 2021 to 31 May 2023. 2,Received Amubarvimab/Romlusevimab (BRII-196/198) administration during hospitalisation after diagnosis of SARS-CoV-2 infection. 3,Age = 18 years. Control group: 1,Patients with SARS-CoV-2 infection admitted to hospital from 1 January 2021 to 31 May 2023. 2,Never had an administration of Amubarvimab/Romlusevimab (BRII-196/198). 3,Age = 18 years.
Exclusion criteria
Exclusion criteria: 1,Refusal to participate in this study. 2,Unable to complete the necessary questionnaires. 3,COVID-19 Vaccination history unknown and lack of clinical information. 4,Death before follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutralizing activity of serum; | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute lymphocyte subsets count;Interleukin-6;COVID-19 IgM and IgG;mMRC dyspnea score;Lung function; | — |
Countries
China
Contacts
Public ContactYonghao Xu
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed